Apotex Expands U.S. Sterile Injectable Manufacturing Through Halo Pharmaceuticals Partnership

Apotex Corp. Has announced a strategic sterile filling partnership with Halo Pharmaceuticals, marking a significant step in the company’s effort to strengthen its domestic manufacturing footprint. This collaboration provides Apotex with access to sterile injectable filling capacity at Halo’s facility in Whippany, New Jersey, supporting the company’s broader “Journey of Health” strategy.

Strengthening Domestic Sterile Manufacturing

The partnership focuses on increasing Apotex’s ability to produce sterile injectables within the United States. By investing in this collaboration, Apotex secures access to a significant portion of the sterile filling capacity currently being installed and qualified at the Whippany site. This move is designed to enhance the company’s infrastructure and research and development capabilities without the need for a “greenfield” development approach—meaning Apotex can utilize existing facilities rather than building new ones from the ground up.

Through this arrangement, Apotex will gain specific access to:

• Vial filling capacity
• Pre-filled syringe filling capacity

Synergies Between Apotex and Halo Pharmaceuticals

This new agreement builds upon a pre-existing relationship between the two companies, which already includes non-sterile manufacturing programs. In this new collaboration, Apotex contributes its expertise in sterile processing, commercialization capabilities, and regulatory readiness. Halo Pharmaceuticals, a provider of development and manufacturing services across various dosage forms, provides the technical infrastructure and filling capacity.

Regulatory Path and Operational Readiness

The Whippany, New Jersey facility is expected to undergo future regulatory inspections as part of its qualification process, following standard FDA requirements. Apotex’s role in the partnership includes supporting technical and operational readiness activities to prepare for these reviews. It’s important to note that the final outcomes of any regulatory inspections or approvals remain subject to FDA determination.

“We are very excited to partner with Apotex on their Made in the U.S. Strategy for injectables,” stated Lee Karras, CEO of Halo Pharmaceuticals.

Key Takeaways: Apotex Strategic Expansion

• Strategic Goal: Strengthening U.S.-based manufacturing and domestic infrastructure.
• Operational Flexibility: Accessing near-term capacity via Halo Pharmaceuticals instead of building new facilities.
• Capacity Focus: Specifically targeting vial and pre-filled syringe sterile filling.
• Location: Operations are centered at the Halo facility in Whippany, New Jersey.

Apotex’s Recent Clinical and Regulatory Milestones

This partnership coincides with a period of rapid growth for Apotex in the U.S. Market. On April 14, 2026, the company announced FDA approval for the first generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) in partnership with Gland Pharma and Orbicular Pharmaceutical Technologies. On April 10, 2026, Apotex received the first U.S. FDA tentative approval for a generic version of Ozempic® (Semaglutide Injection).

Frequently Asked Questions

Does this partnership replace all of Halo Pharmaceuticals’ other clients?
No. Lee Karras, CEO of Halo Pharmaceuticals, confirmed that the company will maintain ample capacity for other customers requiring sterile filling CDMO services for cartridges, syringes, and vials.

What is the purpose of the “Journey of Health” strategy?
The strategy focuses on strengthening domestic manufacturing operations and expanding access to affordable, high-quality pharmaceuticals within the United States.

Looking Ahead

As Apotex continues to expand its portfolio of complex peptide therapies and sterile injectables, the ability to scale domestic production will be critical. The partnership with Halo Pharmaceuticals provides the operational agility needed to bring these essential medications to market more efficiently even as reducing reliance on overseas manufacturing.